Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.50 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.48 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30237383 | 0.88 | SLC28A2 (0.56) | MEN1KMT2ARAPGEF3HSPA5HSPA8 | |
| SCHEMBL30237821 | 0.88 | HSPA8 (0.52) | MEN1KMT2ARAPGEF3HSPA5HSPA8 | |
| SCHEMBL30237705 | 0.88 | SLC28A2 (0.58) | MEN1KMT2ARAPGEF3HSPA5HSPA8 | |
| SCHEMBL5328057 | 0.88 | RAPGEF3 (0.61) | MEN1KMT2ARAPGEF3HSPA5HSPA8 | |
| SCHEMBL30237368 | 0.88 | RAPGEF3 (0.61) | MEN1KMT2ARAPGEF3HSPA5HSPA8 | |
| SCHEMBL5328067 | 0.88 | RAPGEF3 (0.61) | MEN1KMT2ARAPGEF3HSPA5HSPA8 | |
| SCHEMBL30237176 | 0.88 | HSPA8 (0.56) | MEN1KMT2ARAPGEF3HSPA5HSPA8 | |
| SCHEMBL30237448 | 0.88 | HSD17B10 (0.56) | RAPGEF3HSPA5HSPA8RXFP1PDE4A | |
| SCHEMBL30237396 | 0.86 | RAPGEF3 (0.52) | MEN1KMT2ARAPGEF3HSPA5HSPA8 | |
| SCHEMBL30237992 | 0.82 | HSPA8 (0.58) | HSPA5HSPA8RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | MEN1 2953/4885KMT2A 1729/4885RAPGEF3 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.